Clinical Trial Update: A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of PF-05082566 in combination with mogamulizumab in patients with advanced solid tumors was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Mogamulizumab (mogamulizumab)
• PF-05082566 (4-1BB agonist)

Snippet

Sponsor: Pfizer | Conditions: Advanced/Metastatic Solid Tumors | Phase 1 | Status: TERMINATED | Results posted: 2019-02-15